Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity

S Simpson-Yap; A Pirmani; T Kalincik; E De Brouwer; L Geys; T Parciak; A Helme; N Rijke; JA Hillert; Y Moreau; G Edan; S Sharmin; T Spelman; R Mcburney; H Schmidt; AB Bergmann; S Braune; A Stahmann; RM Middleton; A Salter; B Bebo; A Van Der Walt; H Butzkueven; S Ozakbas; C Boz; R Karabudak; R Alroughani; JI Rojas; IA Van Der Mei; G Sciascia Do Olival; M Magyari; RN Alonso; RS Nicholas; AS Chertcoff; AZ De Torres; G Arrambide; N Nag; A Descamps; L Costers; R Dobson; A Miller; P Rodrigues; V Prčkovska; G Comi; LM Peeters

Journal article

Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity

S Simpson-Yap, A Pirmani, T Kalincik, E De Brouwer, L Geys, T Parciak, A Helme, N Rijke, JA Hillert, Y Moreau, G Edan, S Sharmin, T Spelman, R Mcburney, H Schmidt, AB Bergmann, S Braune, A Stahmann, RM Middleton, A Salter Show all

Neurology Neuroimmunology and Neuroinflammation | LIPPINCOTT WILLIAMS & WILKINS | Published : 2022

DOI: 10.1212/NXI.0000000000200021

Download PDF

Abstract

Background and Objective s Certain demographic and clinical characteristics, including the use of some disease-modifying therapies (DMTs), are associated with severe acute respiratory syndrome coronavirus 2 infection severity in people with multiple sclerosis (MS). Comprehensive exploration of these relationships in large international samples is needed. Methods Clinician-reported demographic/clinical data from 27 countries were aggregated into a data set of 5,648 patients with suspected/confirmed coronavirus disease 2019 (COVID-19). COVID-19 severity outcomes (hospitalization, admission to intensive care unit [ICU], requiring artificial ventilation, and death) were assessed using multilevel..

View full abstract

University of Melbourne Researchers

Steve Simpson-Yap Author

Tomas Kalincik Author

Sifat Sharmin Author

Timothy Spelman Author

Related Projects (2)

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

Grants

Awarded by Vlaamse regering

Funding Acknowledgements

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: the operational costs linked to this study are funded by the Multiple Sclerosis International Federation (MSIF) and the Multiple Sclerosis Data Alliance (MSDA), acting under the umbrella of the European Charcot Foundation (ECF). The MSDA receives income from a range of corporate sponsors, recently including Biogen, Bristol-Myers Squibb (formerly Celgene), Canopy Growth Corporation, Genzyme, Icometrix, Merck, Mylan, Novartis, QMENTA, Quanterix, and Roche. MSIF receives income from a range of corporate sponsors, recently including Biogen, Bristol-Myers Squibb (formerly Celgene), Genzyme, Med-Day, Merck, Mylan, Novartis, and Roche. This work was supported by the Flemish Government under the Onderzoeksprogramma Artificiele Intelligentie (AI) Vlaanderen programme and the Research Foundation Fladers (FWO) for ELIXIR Belgium-Flanders (FWO) for ELIXIR Belgium. The central platform was provided by QMENTA, and the computational resources used in this work were provided by Amazon. The statistical analysis was carried out at CORe, The University of Melbourne, with support from NHMRC (1129189 and 1140766).